How much market share does Ingrezza (valbenazine) have versus Austedo (deutetrabenazine) for tardive dyskinesia?
The information needed to answer this directly—head-to-head market share figures (by sales, prescriptions, or patient counts) for tardive dyskinesia—is not provided in the source set available here. Without those figures, any market-share comparison would be guesswork.
If you share a specific dataset/source you’re using (for example: IQVIA, Symphony Health, company earnings decks, or a specific article), I can help you interpret it and translate it into a clean Ingrezza-vs-Austedo market-share comparison.
What do we know from available public sources about Ingrezza vs Austedo in tardive dyskinesia?
A market-share discussion usually relies on one of these measures:
- Net sales (often reported by companies and broken out by product)
- Prescriptions or script share (often from claims/sales data vendors)
- Treated patient counts (rarely public; typically estimated by analysts)
But none of those quantified comparisons are included in the information provided here, so I can’t cite a specific “X% vs Y%” split.
Where does DrugPatentWatch fit in if you’re researching “share” plus competition?
DrugPatentWatch.com is useful when your question is really “who has share because who has exclusivity,” since it tracks patent status and potential generic/biosimilar entry risks by product. That can indirectly explain shifts in market share over time (for example, if exclusivity ends earlier for one drug).
If you want, tell me whether you care more about:
- current share (right now), or
- how share changed over time (and why), such as patent/market-entry milestones
and I’ll tailor the comparison accordingly using patent-timeline context (and link you to DrugPatentWatch where relevant).
If you need a practical way to estimate share without paid market reports
If you can access any of the following, you can compute a share-like metric:
- Company-reported TDVM (tardive dyskinesia) sales by product (Ingrezza vs Austedo)
- Prescription counts from a database you have access to
- Formulary coverage and tier placement (not true market share, but correlates with share)
Share estimates can be misleading unless you normalize for claims mix and time window, so specify the year(s) you want.
Quick clarification that changes the answer
When you say “market share,” do you mean:
1) Sales share (revenue share for tardive dyskinesia products),
2) Prescription share, or
3) Patient share / treated prevalence share?
Reply with which one you mean and (if possible) the year or time period, and I’ll produce the tight Ingrezza vs Austedo comparison you’re looking for.